Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  Nasdaq  >  Moderna, Inc.    MRNA

MODERNA, INC.

(MRNA)
  Report
Delayed Quote. Delayed Nasdaq - 10/29 04:00:00 pm
71.28 USD   +8.43%
03:16aNEWS HIGHLIGHTS : Top Company News of the Day
DJ
02:39aBioNTech CEO expects data from late-stage study soon
RE
01:16aNEWS HIGHLIGHTS : Top Company News of the Day
DJ
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsPress ReleasesOfficial PublicationsSector newsMarketScreener StrategiesAnalyst Recommendations

Pfizer partner BioNTech sees no role for its vaccine in UK challenge trial

share with twitter share with LinkedIn share with facebook
09/24/2020 | 02:03pm EDT

FRANKFURT, Sept 24 (Reuters) - Pfizer's German development partner BioNTech on Thursday joined other leading COVID-19 vaccine developers in ruling out participation in British plans to test experimental inoculations by deliberately infecting trial volunteers.

"BioNTech's vaccine candidate is not part of this study," a spokeswoman said.

Britain is planning to host so-called "challenge trials", the Financial Times cited people involved in the project as saying. Britain said it was working with partners on the potential for human challenge trials without commenting on a specific plan.

AstraZeneca and Sanofi and Moderna , among the leading vaccine developers, have said their vaccine candidates were not involved in the programme.

U.S. biotech firm Inovio Pharmaceuticals also said it was not involved while Johnson & Johnson said it was evaluating the potential benefit of a human challenge trial but would not comment on the British plans.

The World Health Organisation was not involved in such studies, a spokesman said on Thursday.

In a paper https://apps.who.int/iris/bitstream/handle/10665/331976/WHO-2019-nCoV-Ethics_criteria-2020.1-eng.pdf?ua=1 published in May, the WHO said challenge trials could be risky even if limited to young, healthy adults because too little is known about how COVID-19 progresses and there are no specific treatments apart from Gilead's remdesivir.

U.S.-based advocacy group 1Day Sooner, which is lining up volunteers and is lobbying for challenge trials, in a media briefing on Thursday said it did not have confirmation about which vaccines had been eyed for testing in Britain.

Leading vaccine makers have each recruited tens of thousands of volunteers in late-stage trials that rely on accidental infections to yield results on efficacy. (Additional reporting by Trisha Roy and Sri Kalyani Manojna Maddipatla; editing by Thomas Seythal and Alexandra Hudson)


Stocks mentioned in the article
ChangeLast1st jan.
ASTRAZENECA PLC -0.71% 7830 Delayed Quote.3.54%
BIONTECH SE 9.38% 84.81 Delayed Quote.150.32%
INOVIO PHARMACEUTICALS, INC. -3.94% 10.49 Delayed Quote.217.88%
MODERNA, INC. 8.43% 71.28 Delayed Quote.264.42%
PFIZER INC. -0.48% 35.28 Delayed Quote.-9.95%
PFIZER LIMITED -1.04% 5031.65 End-of-day quote.19.12%
SANOFI -0.93% 77.45 Real-time Quote.-12.71%
share with twitter share with LinkedIn share with facebook
All news about MODERNA, INC.
03:16aNEWS HIGHLIGHTS : Top Company News of the Day
DJ
02:39aBioNTech CEO expects data from late-stage study soon
RE
01:16aNEWS HIGHLIGHTS : Top Company News of the Day
DJ
10/29NEWS HIGHLIGHTS : Top Company News of the Day
DJ
10/29NEWS HIGHLIGHTS : Top Company News of the Day
DJ
10/29EU to fund transfer of COVID-19 patients across borders to prevent hospitals ..
RE
10/29EU Commission says talking to four companies on COVID vaccine
RE
10/29Health Care Shares Slip as Trump Sets Rules for Coronavirus Vaccine -- Health..
DJ
10/29Wall Street rebounds as market eyes tech results, strong U.S. data
RE
10/29Wall Street rebounds as market eyes tech results, strong U.S. data
RE
More news
Financials (USD)
Sales 2020 377 M - -
Net income 2020 -725 M - -
Net cash 2020 2 870 M - -
P/E ratio 2020 -37,0x
Yield 2020 -
Capitalization 28 126 M 28 126 M -
EV / Sales 2020 67,0x
EV / Sales 2021 9,70x
Nbr of Employees 975
Free-Float 89,9%
Chart MODERNA, INC.
Duration : Period :
Moderna, Inc. Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends MODERNA, INC.
Short TermMid-TermLong Term
TrendsNeutralNeutralBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 15
Average target price 91,53 $
Last Close Price 71,28 $
Spread / Highest target 90,8%
Spread / Average Target 28,4%
Spread / Lowest Target -42,5%
EPS Revisions
Managers
NameTitle
Stéphane Bancel Chief Executive Officer & Director
Stephen Hoge President
Noubar B. Afeyan Chairman
David W. Meline Chief Financial Officer
Juan Andres Chief Technical Operations & Quality Officer
Sector and Competitors
1st jan.Capitalization (M$)
MODERNA, INC.264.42%28 126
LONZA GROUP AG56.63%44 852
SEAGEN INC.68.34%33 467
CELLTRION, INC.39.78%29 849
IQVIA HOLDINGS INC.0.09%29 650
IMMUNOMEDICS, INC.315.22%20 324